Bausch Health Cos Inc. $BHC Shares Purchased by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC significantly increased its stake in Bausch Health Cos Inc. by 4,134.7%, acquiring over 657,416 additional shares and now owning a total of 673,316 shares valued at approximately $4.35 million.
• Bausch Health reported earnings per share of $0.90 for the last quarter, falling short of analysts' expectations, though its revenue was higher than estimates at $2.57 billion.
• Director John Paulson made a substantial purchase of 34.7 million shares, increasing his ownership in Bausch Health by 96.35% and reflecting a strong confidence in the company's future.

Acadian Asset Management LLC boosted its stake in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 4,134.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 673,316 shares of the company's stock after buying an additional 657,416 shares during the period. Acadian Asset Management LLC owned approximately 0.19% of Bausch Health Cos worth $4,347,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock valued at $2,102,000 after acquiring an additional 9,834 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock valued at $6,136,000 after acquiring an additional 467,270 shares in the last quarter. Jones Financial Companies Lllp grew its position in Bausch Health Cos by 1,548.9% in the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock valued at $162,000 after acquiring an additional 23,451 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Bausch Health Cos in the 1st quarter valued at about $68,000. Finally, Cubist Systematic Strategies LLC grew its position in Bausch Health Cos by 162.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 607,656 shares of the company's stock valued at $3,933,000 after acquiring an additional 376,518 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bausch Health Cos

In related news, Director John Paulson acquired 34,721,118 shares of the stock in a transaction dated Thursday, August 14th. The stock was acquired at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares in the company, valued at $636,802,821. This represents a 96.35% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders bought 37,964,167 shares of company stock worth $333,757,793 over the last three months. Insiders own 19.97% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Bausch Health Cos has an average rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Stock Down 2.3%

Shares of Bausch Health Cos stock traded down $0.16 on Friday, reaching $6.73. 1,404,712 shares of the company were exchanged, compared to its average volume of 2,073,771. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $9.85. The company has a market cap of $2.49 billion, a P/E ratio of 25.89 and a beta of 0.48. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The stock's 50 day moving average price is $6.90 and its 200-day moving average price is $6.09.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The company had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.